Table 3. Clinicopathological features by first-line treatment regimens after matching.
| Variables | Platinum plus etoposide, n=57 | Platinum plus irinotecan, n=57 | P value |
|---|---|---|---|
| Median age, years (range) | 68.0 (53.0–80.0) | 67.0 (50.0–83.0) | 0.025 |
| Age categorization, years, n (%) | 1 | ||
| <75 | 53 (93.0) | 53 (93.0) | |
| ≥75 | 4 (7.0) | 4 (7.0) | |
| Sex | 1 | ||
| Male | 38 (66.7) | 38 (66.7) | |
| Female | 19 (33.3) | 19 (33.3) | |
| ECOG PS =0, 1, n (%) | |||
| At first-line treatment initiation | 54 (94.7) | 54 (94.7) | 1 |
| At AMR initiation | 51 (89.5) | 51 (89.5) | 1 |
ECOG PS, Eastern Cooperative Oncology Group performance status; AMR, amrubicin.